Abstract:BACKGROUND: In 1998 we estimated that 34/million infectious window period donations were entering the blood supply at the South African National Blood Service. Selective use of donations based on donor race-ethnicity reduced this risk to 26/million donations but was deemed unethical. Consequently, in 2005 South African National Blood Service eliminated race-ethnicity-based collection policies and implemented individual-donation nucleic acid testing (ID-NAT). We describe the change in donor base demographics, human immunodeficiency virus (HIV) detection rates, and transfusion-transmissible HIV risk.STUDY DESIGN AND METHODS: In ten years 7.7 million donations were tested for anti-HIV and HIV RNA. Number of donations, HIV prevalence, ID-NAT yield rate, serology yield rate and residual transfusion-transmissible HIV risk were analyzed by donor type, race-ethnicity, age, and sex. Multiple regression analysis was performed to investigate the determinants of HIV-positive and nucleic acid testing yield donations.RESULTS: The combined strategy of increasing donations from black donors and implementing ID-NAT increased the proportion of donations from black donors from 6% in 2005 to 30% in 2015 (p < 0.00001), and reduced the transfusion-transmissible risk from 24 to 13 per million transfusions. ID-NAT interdicted 481 (1:16,100) seronegative window period donations, while one transfusion-transmissible case (0.13 per million) was documented. Race-ethnicity and donor type were highly significant predictors of HIV positivity, with adjusted odds ratio for first-time donors of 12.5 (95% confidence interval, 11.9-13.1) and for black race-ethnicity of 31.1 (95% confidence interval, 28.9-33.4). The proportion of serology yields among HIV-infected donors increased from 0.27% to 2.4%.CONCLUSION: ID-NAT enabled the South African National Blood Service to increase the number of donations from black donors fivefold while enhancing the safety of the blood supply.

Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group

Current safety of clotting factor concentrates

ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE

A Study on transmission of human immunodeficiency virus (HIV) by blood transfusion

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group

Transfusion-Associated HIV Infection in Pediatric Leukemia Patients (two Case Reports).

Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors

Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates.

A Seral Epidemiological Study of HIV Transmitted Through Human Seral ΓGlobulin Preparations

Divergence of HIV-1 quasispecies in an epidemiologic cluster.

Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic Testing

The prevalence of hepatitis B virus, human T-lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa

Molecular Identification of Transmitted/Founder Viruses by Single Genome Amplification Following Percutaneous Occupational Exposure to Hiv-1

A Retrospective Cohort Study on the Natural History of Human Immunodeficiency Virus among Formal Plasma Donors in Central China

Proceedings of a consensus conference: blood-borne HIV and hepatitis-optimizing the donor selection process

Prevention of transfusion-transmitted infections

Assessment of HIV transfusion transmission risk in South Africa: a 10‐year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes

[Retrospective Cohort Study on the Rate of Mother-to-child Transmission among Mothers Infected with Human Immunodeficiency Virus Type 1 Through Blood Transfusion].

Transfusion medicine and safety

[Following surveillance on HIV infection after blood transfusion]

The Molecular Epidemiology of Human Immunodeficiency Virus Type 1 in Edinburgh.